Table 1.
Baseline characteristics at the start of immune checkpoint inhibitor therapy
| Characteristics | Entire cohort (n=119) | Patients with available genomic data (n=78) |
| Age, years—median (IQR) | 71 (65, 77) | 71 (66, 76) |
| Male—n (%) | 77 (64.7) | 49 (62.8) |
| Female—n (%) | 42 (35.3) | 29 (37.2) |
| Smoking history (present or former)—n (%) | 71 (59.7) | 46 (59.0) |
| Ethnicity—n (%) | ||
| White | 81 (68.1) | 54 (69.2) |
| Asian | 19 (16.0) | 12 (15.4) |
| African American | 6 (5.0) | 5 (6.4) |
| Hispanic | 4 (3.4) | 2 (2.6) |
| Other | 7 (5.9) | 4 (5.1) |
| Primary bladder tumor—n (%) | 90 (75.6) | 57 (73.1) |
| Upper tract disease—n (%) | 29 (24.4) | 21 (26.9) |
| Cystectomy or nephroureterectomy—n (%) | 63 (52.9) | 47 (60.3) |
| Histology—n (%) | ||
| Pure urothelial histology | 77 (64.7) | 47 (60.3) |
| Mixed variant histology | 36 (30.3) | 27 (34.6) |
| Pure variant histology | 6 (5.0) | 4 (5.1) |
| Immunotherapy treatment setting—n (%) | ||
| Front-line metastatic | 58 (48.7) | 37 (47.4) |
| Postplatinum | 61 (51.3) | 41 (52.6) |
| ECOG PS—n (%) | ||
| 0–1 | 66 (55.5) | 49 (62.8) |
| ≥2 | 25 (21.0) | 11 (14.1) |
| Unknown | 28 (23.5) | 18 (23.1) |
| Visceral metastases—n (%) | 90 (75.6) | 55 (70.5) |
| BMI, kg/m2—median (IQR) | 24.9 (22.0, 28.6) | 25.2 (22.0, 28.8) |
| Hemoglobin <100 g/L—n (%) | 37 (31.1) | 26 (33.3) |
| Creatinine, mg/dL—median (IQR) | 1.35 (1.03, 1.75) | 1.41 (1.09, 1.78) |
| Albumin, g/dL—median (IQR) | 3.4 (3.0, 3.8) | 3.6 (3.0, 3.8) |
| NLR <5—n (%) | 65 (54.6) | 46 (59.0) |
BMI, body mass index; NLR, neutrophil to lymphocyte ratio; ECOG PS, Eastern Cooperative Oncology Group performance status.